41
Participants
Start Date
March 14, 2019
Primary Completion Date
October 18, 2021
Study Completion Date
June 14, 2023
belantamab mafodotin
belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
Pembrolizumab
Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
GSK Investigational Site, Berlin
GSK Investigational Site, Hamburg
GSK Investigational Site, Charlotte
GSK Investigational Site, Pozuelo de Alarcón/Madrid
GSK Investigational Site, Atlanta
GSK Investigational Site, Hanover
GSK Investigational Site, Salamanca
GSK Investigational Site, Indianapolis
GSK Investigational Site, Madison
GSK Investigational Site, Calgary
GSK Investigational Site, Toronto
GSK Investigational Site, Badalona
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
GlaxoSmithKline
INDUSTRY